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Edited by Michael R. BubbAbstract DC-SIGN (dendritic cell-speciﬁc ICAM-3 grabbing
non-integrin) is a C-type lectin receptor of dendritic cells and
is involved in the initial steps of numerous infectious diseases.
Surface plasmon resonance has been used to study the aﬃnity
of a glycodendritic polymer with 32 mannoses, to DC-SIGN.
This glycodendrimer binds to DC-SIGN surfaces in the submi-
cromolar range. This binding depends on a clustered organiza-
tion of DC-SIGN mimicking its natural organization as
microdomain in the dendritic cells plasma membrane. Moreover,
this compound inhibits DC-SIGN binding to the HIV glycopro-
tein gp120 with an IC50 in the micromolar range and therefore
can be considered as a potential antiviral drug.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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DC-SIGN (dendritic cell-speciﬁc ICAM-3 grabbing non-
integrin) is a C-type lectin able to recognize high glycosylated
proteins, especially those presenting high mannose structures
such as the viral envelop glycoproteins gp120 (HIV) [1], GP1
(Ebola) [2] or glycoprotein E (Dengue) [3]. A few years ago,
in vitro studies carried out by van Kooyk et al. suggested a role
for DC-SIGN in HIV infection [1]. New evidences have dem-
onstrated that this lectin is able to interact with a large number
of pathogens such as virus, bacteria, fungi and parasites as well
[4]. The broad pathogen spectrum that could use DC-SIGN
during their infection process places this lectin as new target
in infectious diseases.
DC-SIGN, expressed at the surface of dendritic cells, has a
C-terminus carbohydrate recognition domain (CRD). Ultra-
centrifugation [5] and hydrodynamic [6] studies have demon-
strated that this protein oligomerize into homotetramers thus
presenting four CRDs. Moreover, at the plasma membrane le-
vel, DC-SIGN is organized in microdomains, within lipids
rafts, proposed to act as docking site for pathogens [7]. The
interaction of this C-type lectin with high mannose structures
displayed by the pathogen glycoproteins is multivalent and cal-*Corresponding authors. Fax: +34 954 46 05 65 (J. Rojo),
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doi:10.1016/j.febslet.2006.03.061cium dependent [5,8]. Inhibition of this interaction could be
considered as new strategy to design compounds with antiviral
activity. In this aim, a multivalent presentation of mannosyl
oligosaccharides on an adequate scaﬀold mimicking the natu-
ral organization of high mannose structures should be re-
quired. Taking this into account, we have recently described
the synthesis of mannosyl glycodendritic structures based on
second and third generations of Boltorn hyperbranched den-
dritic polymers (BH20 and BH30) that have been functional-
ized with mannose (Fig. 1) [9].
These compounds showed a high solubility in physiological
conditions and no cytotoxicity against several cell lines [9]. We
have also demonstrated that at least the third generation with
32 mannoses at the surface (BH30sucMan) inhibited the infec-
tion process of pseudotyped viral particles presenting the Ebo-
la viral glycoprotein GP1 at the surface [10,11]. This inhibition
presumably occurs through the blockage, by the glycodendritic
polymer BH30sucMan, of the receptor DC-SIGN expressed by
the target cell surface. To further investigate this binding at the
molecular level, we adopted a method in which DC-SIGN is
coupled to a solid phase, at diﬀerent density, and BH30suc-
Man binding is analysed by surface plasmon resonance
(SPR). Biosensors have already been successfully applied to
study carbohydrate–protein interactions [12] including DC-
SIGN [13] and to determine the kinetic and thermodynamic
parameters. Surfaces functionalized with increasing DC-SIGN
density may mimic, to some extend, the presentation of DC-
SIGN as microdomain at the cell surface, but also enable us
to analyse possible ‘‘avidity’’ for mannose carrying molecule
if binding occurs at more than one site and the role of multi-
valency from the point of view of the receptor. This informa-
tion could be very useful to improve the design of better
inhibitors for this protein.2. Materials and methods
2.1. Multivalent compounds
Synthesis of dendritic compounds BH20sucL, BH30sucL, BH20suc-
Man and BH30sucMan have been previously described [9].
2.2. Expression of CRD and ECD of DC-SIGN in Escherichia coli
Plasmids pET30b (Novagen) containing cDNA encoding CRD (cor-
responding to aminoacids 254–404) or extracellular domain (ECD)
(corresponding to aminoacids 66–404) of DC-SIGN were used for
overproduction as described previously [14]. Proteins produced in
inclusion bodies have been refolded as already described [5]. Puriﬁca-
tion of functional DC-SIGN proteins were achieved by an aﬃnityblished by Elsevier B.V. All rights reserved.
Fig. 1. Chemical structures of dendritic compounds. (A) structure of
the hyperbranched polymer BoltornH20 and BoltornH30. (B) Sche-
matic representation of BH20sucL, BH30sucL, BH20sucMan and
BH30sucMan.
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25 mM Tris–HCl, pH 7.8, 150 mM NaCl, 4 mM CaCl2 (Buﬀer A)
and eluted in same buﬀer lacking CaCl2 but supplemented with
10 mM EDTA. This step was followed by a superose 6 size exclusion
chromatography equilibrated in buﬀer A.
2.3. Biosensor experiments
All experiments were performed on a BIAcore 3000 using function-
alized CM4 chips and the corresponding reagents from BIAcore. Four
ﬂow cells were activated as described [14]. Flow cell one was then
blocked with 50 ll of 1 M ethanolamine and served as a control sur-
face. For binding assays, the three other ones were treated with the
ECD (60 or 6 lg/mL) or CRD (57 lg/mL) of DC-SIGN in 10 mM ace-
tate buﬀer, pH 4. Diﬀerent amounts of immobilized protein were ob-
tained by varying the injected volume. Flow cell 2 was functionalized
with DC-SIGN CRD at ‘‘high density’’ (CRD-HD, 600 RU immobi-
lized), ﬂow cell 3 and 4 were functionalized with DC-SIGN ECD at
high and low density, respectively (4920 and 750 RU immobilizedfor ECD-HD and ECD-LD, respectively). Remaining activated groups
were blocked with 50 lL of 1 M ethanolamine. For controlling surface
activity, gp120 protein was injected at 25 lg/mL for 2 min over for the
association phase, after which running, buﬀer alone was injected for
the dissociation phase. For binding studies, glycodendritic polymers
were solubilized in running buﬀer (buﬀer A supplemented with
0.005% P20 surfactant) and injected at 10 lL/min. The curve ﬁtting
has been done using BIAeval program.
For gp120 binding inhibition assays, EDC/NHS activated ﬂow cells
were treated with gp120 HXB2 (5–50 lg/mL) in 10 mM acetate buﬀer,
pH 4. The ECD of DC-SIGN was co-injected with increasing amount
of glycodendritic polymers at 20 lL/min, in running buﬀer, on gp120
ﬂow cells of increasing density.
2.4. Analytical ultracentrifugation experiments
Sedimentation velocity experiments were performed in a Beckman
XL-I analytical ultracentrifuge using an AN-60 TI rotor (Beckman
instruments), at 20 C. Samples were handled in the size exclusion
chromatography elution buﬀer (buﬀer A). The molar mass and partial
speciﬁc volume of DC-SIGN ECD tetramer were estimated from
the aminoacid composition to be MP = 154858 g/mol and
vP ¼ 0:731 ml=g, respectively, using the Sednterp software (available
at www.bbri.org/RASMB/rasmb.html). The partial speciﬁc volume
for the protein–BH30sucMan complex, vcomplex, was approximated to
the one of the protein alone considering the 10 times ratio in molecular
mass in favor of the protein.
Sedimentation velocity experiments were carried out at 42000 rpm,
using 100 or 400 ll protein samples, loaded, respectively, in the two-
channel 0.3 or 1.2 cm path length centerpieces equipped with sapphire
windows, and followed at 5 min interval using absorbance and interfer-
ence optics. Absorbance scans were recorded overnight at 252 or
280 nm (depending on the protein concentration) with a radial step size
of 0.003 cm. Sedimentation velocity proﬁles were analyzed using the
size distribution analysis from the program Sedﬁt (version 9.2 devel-
oped by Schuck and available at www.analyticalultracentrifuga-
tion.com) providing a continuous distribution of apparent
sedimentation coeﬃcients, c(s) [15]. Typically 20 regularly spaced
experimental proﬁles obtained for a total of 6 h sedimentation were
globally modeled. The continuous distribution of apparent sedimenta-
tion coeﬃcients (c(s)) analysis was performed considering 200 particles
on a grid of 300 radial points, calculated with a frictional ratio f/f0 of
2.3 (ﬁtted in Sedﬁt and corresponding to a very elongated shape as pre-
viously demonstrated for DC-SIGN ECD [6]). For the regularization
procedure a conﬁdence level of 0.7 was used.3. Results
3.1. BH30sucMan interacts with DC-SIGN functionalized
surfaces in a multivalent and surface density dependance
We have produced two diﬀerent forms of DC-SIGN: the
monomeric CRD and the tetrameric ECD. These two forms
enabled us to analyze the binding mode since the CRD possess
only one binding site while the tetrameric ECD contains four
sites for carbohydrates ligands and can promote multivalent
binding. These proteins (CRD and ECD) were overexpressed
as inclusion bodies in E. coli, refolded, puriﬁed and used to
functionalize biosensor surfaces (see Section 2). We have pre-
pared three diﬀerent types of surfaces, with these two proteins,
using a carboxydextran CM4 chip from BIAcore (see Section 2
for details). The ﬁrst two ﬂow cells where functionalized with
two diﬀerent level of DC-SIGN ECD and are referred as high
density ECD and low density ECD surfaces. The third one was
functionalized with DC-SIGN CRD at a molecular density
corresponding to the high density tetrameric ECD surface.
Thus, this surface is then designed as high density monomeric
CRD surface. Despite a same density in protein molecules for
the two high density surfaces, the DC-SIGN ECD surface, as a
consequence of its tetrameric organization, displays 4 times
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These three surfaces are active, as shown by their ability to
bind gp120 envelope protein from HIV (Fig. 2A and B), dem-
onstrating that the immobilization process is compatible with
the protein activity. These surfaces have then been used to test
the binding properties of diﬀerent dendrimeric compounds.
Dendritic structures without carbohydrates (BH20sucL and
BH30sucL) did not signiﬁcantly bind to any of the three sur-
faces (not shown). The second generation with 16 mannoses
at the surface (BH20sucMan) showed almost the same behav-
ior than the controls (not shown). Dendritic compounds with
32 mannoses (BH30sucMan) clearly interact with the high den-
sity tetrameric ECD surface. However, despite a similar den-
sity of protein, the monomeric CRD surface was not
signiﬁcantly recognized by BH30sucMan, suggesting a multi-
valent mode of interaction for BH30sucMan. These data show
that a high density and proximity of CRD domain are essential
to promote this multivalent binding. This is supported by the
fact that when increasing further the density of DC-SIGN
CRD on a sensor chip, it is possible to obtain BH30sucMan
binding as observed (in Fig. 2D) with the high density DC-
SIGN ECD surface (data not shown). Adding EDTA to the
ﬂow buﬀer allowed calcium removal from the active site and
the destruction of the interaction between the glycodendritic
structure and DC-SIGN.
To analyze the interaction of BH30sucMan with DC-SIGN,
a range of dendrimer concentrations was injected over the high
density tetrameric ECD surface. Visual inspection of the sen-Fig. 2. SPR analysis of the interaction properties of DC-SIGN surfaces as a f
functionalization. (A) Schematic representation of the three functionalized
interaction with the three surfaces. The gp120 protein was injected at 25 lg/
interacting with BH30sucMan. (D) Sensorgram for binding process of BH3
three surfaces.sorgrams (Fig. 3) showed that BH30sucMan bound to the
immobilized DC-SIGN and formed stable complexes (low dis-
sociation). The binding curves have been analysed using sev-
eral kinetic model and allow to evaluate an apparent Kd in
the submicroMolar range for this type of surface with clus-
tered DC-SIGN ECD (with an average values between the dif-
ferent model used around 100 nM) (see Table S.I and ﬁgure
S.1 of supplementary material). Fitting of the binding curves
to any of the standard model was not obvious since the bind-
ing mechanism between multivalent BH30sucMan and diﬀer-
ent randomly presented CRD on the tetrameric high density
ECD surface (thus generating several types of binding sites)
is most probably a complex combination of the diﬀerent bind-
ing models used.
3.2. Conﬁrmation of bridging interaction of BH30sucMan
between DC-SIGN ECD complexes in solution using
sedimentation velocity
Analytical Ultracentrifugation experiments were performed
to investigate the formation of complex between the protein
and BH30sucMan. Continuous distribution of sedimentation
coeﬃcients were used to describe the sample homogeneity
and evolution. Firstly, measurements were done on DC-SIGN
ECD alone at four concentrations ranging from 1.2 to 21 lM.
The protein was homogenous at all concentrations with s20,w
value at low concentration of 5.4 S. Analysis in terms of sedi-
mentation and diﬀusion coeﬃcients provided a molar mass of
148 kDa, very close to the 155 kDa theoretical value of a tetra-unction of the oligomerization form, ECD and CRD, and the density of
surfaces interacting with gp120. (B) Sensorgram for DC-SIGN/gp120
mL. (C) Schematic representation of the three functionalized surfaces
0sucMan (injected at a concentration of 130 lM for 20 min) with the
Fig. 3. Surface plasmon resonance analysis of BH30sucMan/DC-
SIGN interactions. The BH30sucMan used at concentrations of 10,
7.5, 5, 2.5, 1, and 0.5 lM were injected for 20 min over a DC-SIGN
ECD high density activated surface (7260 RU immobilized).
Fig. 4. Sedimentation velocity of DC-SIGN ECD in the presence or
absence of BH30sucMan. (A) Superimposition of experimental sedi-
mentation proﬁles and the ﬁtted curves from the c(s) analysis (using
Sedﬁt) of DC-SIGN ECD at 35 lM in the presence of 50 lM of
BH30sucMan. (B) Superimposition of the diﬀerences between the
experimental and ﬁtted curves from (A); (C) and (D) c(s) analysis using
absorbance or interference optics, respectively. c(s) presented are DC-
SIGN ECD alone (21 lM) or in the presence of 50 lM of BH30suc-
Man at 12 and 35 lM (continuous, dashed and dotted lines,
respectively). The distributions are normalised to the main peak values.
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mer mass for the tetramer provided a Stokes radius of
6.8 nm and a frictional ratio f/f 0 of 1.9. The corresponding va-
lue for a globular compact protein is 1.2–1.3. The large f/f 0 is
in agreement with the very elongated shape of DC-SIGN pre-
viously described [6]. At high concentration of 21 lM, the s20,w
value decreased slightly to 5.1 S, which was expected from
excluded volume eﬀect. There was no indication of any auto-
association: the c(s) proﬁle showed only one peak (Fig. 4, pan-
els C and D). The glycodendrimer by itself sedimented slower,
with a mean s20,w-value of 2.8 S, which was evidenced using
interference optics, since it does not display signiﬁcant absor-
bance properties (data not shown).
The c(s) distribution for two mixtures, with a conserved con-
centration of dendrimer of 50 lM is compared to that of DC-
SIGN ECD on Fig. 4. Panel A shows for one of the mixtures a
selection of the sedimentation proﬁles and their modeling, pa-
nel B the residuals (superimposition of the diﬀerences between
the experimental and ﬁtted curves). Panels C and D give the
superimposition of the c(s) for the three samples using absor-
bance and interference optics, respectively. Although the de-
tails of the distribution diﬀer slightly, the same main features
are observed whatever the detection used. The complexation
is obvious, with average s20,w values of 5.1 S for DC-SIGN
ECD alone, going to 5.4 and 6.3 S in the presence of 50 lM
dendrimer with increasing DC-SIGN ECD concentrations of
12 and 35 lM, respectively. Peaks are broader for the com-
plexes, this can have diﬀerent origins and will not be analyzed
further. The c(s) analysis from interference suggests that
increasing the concentration of DC-SIGN ECD at constant
concentration of BH30sucMan, the proportion of a species
at 6.3 S increases at the expense of others at around 5.4 S.
The c(s) analysis also shows a limited proportion of aggregates
with s20,w-values above 8 S.
To interpret the c(s) analysis, we compared the experimental
s-scale with calculated values for diﬀerent complexes. We
approximated the f/f 0 and partial speciﬁc volume to the values
of DC-SIGN ECD, which represents the main part of the com-
plexes (its molar mass being more than ten times that of the
glycodendrimer). Then we have calculated for diﬀerent DC-
SIGN ECD:BH30sucMan stoichiometries of 1:1, 2:1 and 1:4,
theoretical s-values of 5.4, 8.3, and 6.5 S, respectively. The ﬁrst
value is close to that of the 5.3 S peaks on panel D suggesting
that the peak correlates with a 1:1 complex. The second is
much larger and the third one close to that of the 6.3 S exper-
imental peak. The discrepancy between the second theoreticalvalue and the experimental one could be related to an underes-
timated f/f 0 value (a complex comprising 2 DC-SIGN ECD
moieties could be more anisotropic than 1 DC-SIGN ECD).
Alternatively, the saturation of the equilibrium might have
not been reached, and/or association dissociation phenomena
in the ultracentrifuge could have provided peaks in the c(s)
proﬁles below the characteristic s-values for the 2:1 complex.
The 6.3 S can only be considered as a minimal value character-
izing the complexed species. The third calculation corresponds
to a complex comprising an excess of 4 BH30sucMan, since
DC-SIGN ECD has 4 sugar binding site and BH30sucMan
concentration corresponds to a large excess of sugar moieties
in the solutions (32 mannose per compounds · 50 lM =
1.6 mM of mannose ends), and leads to a calculated s value
closer to the experimental one. From our set of experimental
data, the analysis of the s-values by itself does not allow to dis-
criminate between complexes comprising an excess of DC-
SIGN ECD versus an excess of BH30sucMan.
More insight on the complex composition can be obtained
from the analysis of the intensity obtained by absorbance (A)
and interference (J). We have globally analyzed the main spe-
cies of s between 4 and 7 S. Sedimentation velocity data for the
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Man 35 lM:50 lM were obtained at a common wavelength
of 252 nm. J/A252 nm changed only slightly: for the protein
J/A = 3.9 and for the mixture: J/A = 4.0. From A252 nm and
interference signals of DC-SIGN and BH30sucMan alone, the-
oretical J/A ratios have been calculated for diﬀerent complex
stoichiometries. Going from DC-SIGN ECD:BH30sucMan
complexes with an excess of glycodendrimer (1:2) to complexes
with increasing proportion of protein (1:1, 2:1, and 3:1 stoichi-
ometry), theoretical J/A ratio are 4.28, 4.11, 4.02, 3.99, respec-
tively. The comparison with the experimental value of 4.0
suggests that the mixture has globally an excess of DC-SIGN
ECD over BH30sucMan, and not the contrary.
In summary, the experiments show complexes in solution of
moderate sizes, even if a small proportion of large assembliesFig. 5. Inhibition of the DC-SIGN/gp120 interactions. DC-SIGN
ECD at 45 lM is incubated 1 h with (A) BH30sucMan or (B)
BH30sucL at concentrations 0, 3.5, 14, 28, 57, 85, 128 lM and co-
injected on a gp120 functionalized surface (176 RU immobilized). (C)
Comparison of the inhibitory power of the diﬀerent dendritic and
glycodendritic polymers towards the DC-SIGN/gp120 interaction. (s)
BH30sucL, (n) BH20sucL, (m) BH20sucMan, (d) BH30sucMan.are detected. Combining the analysis in terms of s-values and
J/A ratio indicates complexes of DC-SIGN bridged by
BH30sucMan.
3.3. Inhibition of DC-SIGN:gp120 interaction by BH30sucMan
After analyzing the binding of our dendritic compounds to
the receptor DC-SIGN, we have studied the interaction of
DC-SIGN with the HIV viral glycoprotein gp120 in competi-
tion with the synthetic glycodendritic compounds. To perform
the competition experiments, we have functionalized the bio-
sensor chip with gp120 and co-injected increasing amounts
of the multivalent compounds together with a ﬁxed concentra-
tion of DC-SIGN ECD. When we use the dendritic control
BH30sucL without carbohydrates, the sensorgrams demon-
strated that this compound is not able to inhibit the binding
of ECD with gp120 and for all concentrations of the control
tested the curves remain unchanged (Fig. 5B and C). In the
presence of BH30sucMan, the binding response decrease with
the increasing amounts of this compound, indicating an ECD
binding inhibition with the gp120 surface (Fig. 5A and C).
From the analysis of the curves it is possible to estimate an
IC50 for BH30sucMan of 50 lM (Fig. 5C). Moreover, using
surface functionalized with increasing density of gp120 lead
to an increase of the BH30sucMan IC50 (see ﬁgure S.2 supple-
mentary materials).4. Discussion
We have been able to prove the binding of our glycoden-
dritic structures (the analyte) to a surface functionalized with
DC-SIGN and showed that at least 32 mannoses and a high
density of DC-SIGN are required for the binding. These re-
sults clearly conﬁrm that this binding is calcium and carbohy-
drate dependent and therefore is likely to take place through
the carbohydrate recognition domain of the protein. Also, it
demonstrates that BH30sucMan binding is multivalent and
can be achieved only if the number of displayed CRD units
is high enough. However, it does not interact with the four
CRD units present within one molecule of tetrameric ECD
since no binding was observed on the low density tetrameric
ECD surface (Fig. 2D). Multivalency on the high density tet-
rameric ECD surface was thus probably achieved in a bridging
manner using CRD units belonging to diﬀerent tetrameric
ECD molecules on the surface (Fig. 2C). Therefore, the density
of tetrameric ECD is crucial to promote BH30sucMan binding
as shown by comparison between the low and high density
surfaces.
This binding analysis conﬁrms the idea that the binding is
multivalent and require a close proximity of independent
CRD in space (CRD belonging to the same tetramer are not
close enough or are not adequate oriented with respect to
the three others to allow a binding to our glycodendritic poly-
mer as deduced by the absence of binding with a low density
ECD surface). In fact, this type of surface (high density of
ECD) presumably better mimics the natural organization of
DC-SIGN in microdomains at the cell surface clustered into
speciﬁc regions denoted as lipid rafts [7].
Using this binding assay we also set up a competition assay
in which diﬀerent glycodendritic structures were analysed for
their ability to inhibit the gp120/DC-SIGN interaction. Previ-
ous studies have demonstrated the application of SPR to ana-
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cytomegalovirus (CMV), hepatitis C (HCV) with DC-SIGN
[3,14,16]. The glycoprotein gp120 at the surface of HIV is a
highly glycosylated viral protein with several high mannose
N-glycan structures. This viral protein displays an aﬃnity con-
stant in the nM range for DC-SIGN and this binding is a crit-
ical step used by HIV in T-cell trans-infection using dendritic
cells as intermediates [1]. Competitions experiments enabled
us to determine whether the glycodendritic structures can inhi-
bit the recognition process between gp120 and DC-SIGN and
could be used as an antiviral compounds inhibiting the infec-
tion process at one of the earliest stages. The IC50 value found
in the competition experiments (50 lM) is higher than ex-
pected considering the apparent Kd, in the sub-micromolar
range, evaluated from kinetic analysis (see supplementary
material). In this set up, DC-SIGN ECD are not pre-organized
on a surface but are free in solution. In that situation multiva-
lency of binding with respect to DC-SIGN ECD can not be
easily achieved, leading to a less eﬃcient binding of the glyco-
dendrimers. In similar experimental conditions, with respect to
the relative concentrations of DC-SIGN ECD and BH30suc-
Man, sedimentation velocity experiments allowed us to con-
ﬁrm in solution the capacity of BH30sucMan to promote the
bridging of DC-SIGN ECD in assembly of moderate size
but also of small amount of bigger complexes. This DC-SIGN
ECD sequestering can account for the inhibitory eﬀect of
BH30sucMan in our competition assay. Because of the context
of a solution, this BH30sucMan bridging eﬀect is achieved at
higher concentration than with a functionalized surface. How-
ever, despite an under estimation of the real inhibiting capac-
ity, this test proves its ability to compare relative eﬃciency
between series of dendrimeric compounds (Fig. 5C). Using sur-
face functionalized with increasing density of gp120 lead to an
increase of the BH30sucMan IC50 suggesting that with the in-
crease of gp120 density appears an increase of the multivalent
binding for the free tetrameric DC-SIGN ECD and appear-
ance of an avidity binding mechanism (Fig. S2 of supplemen-
tary material). So, the lower the gp120 density is, the better the
inhibitory power of BH30sucMan will be. Electron tomogra-
phy studies of HIV-1 virion revealed an average of 8–10 tri-
mers of gp120 at the virus surface [17]. This natural low
density of the envelope glycoprotein at the virion surface
strengthens our inhibitory approach using glycodendrimeric
compounds.
Using SPR we have demonstrated that the third generation
of the Boltorn hyperbranched dendritic polymer functional-
ized with 32 mannoses binds to DC-SIGN with an apparent
aﬃnity in the sub microMolar range and is capable to inhibit
the interaction of DC-SIGN to gp120. The level of apparent
aﬃnity reaches with the third generation of the Boltorn poly-
mer conﬁrms us in the choice of this scaﬀold for a multivalent
presenting system. After this proof of concept where submi-
cromolar apparent aﬃnity have been reach presenting the sim-
plest carbohydrate ligand of DC-SIGN (a monosaccharide),
compounds with very high aﬃnity and speciﬁcity can be ex-
pected by using more complex and DC-SIGN speciﬁc carbohy-
drate moiety. Additional improvement might be obtained by
modifying the linker and the multivalent scaﬀold. Moreover,
we have set up DC-SIGN surfaces that represented good mim-
ics of the DC-SIGN microdomains of the plasma membrane.
Such surfaces will be important tools in the objective to study
interaction properties of such microdomains and for the eval-uation of new compounds speciﬁc for this type of DC-SIGN
organization. These preliminary results encourage us to pur-
suit the development of better inhibitors that should be able
to block the HIV binding to dendritic cells and can be used
as microbicides. With the help of biosensors, the analysis of
new candidates will help us to select the best one to go to
further in vitro and in vivo inhibitory studies.
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